John Martin - 2010 CEO Pay

John C. Martin

John Martin - Gilead Sciences

Total Compensation: $14.2 million

Details: John Martin's compensation was down a little in 2010 from 2009, when his package was worth just under $14.7 million; last year, it was $14.2 million. Martin earned a salary of a little more than $1.3 million last year--up from $1.24 million in 2009. He also received stock and option awards of roughly $10.5 million--down from the previous year, when he snagged more than $11.1 million.

As Dow Jones notes, Gilead is known for its HIV drugs and saw its net income rise 10 percent to $2.9 billion on revenue growth of 13 percent to $7.9 billion.

Gilead Sciences News:
Truvada fails trial to prevent HIV in women
Who's the biggest HIV drug seller of all?

John Martin - 2010 CEO Pay

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.